anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
1,186,938. Tertiary 1,3-aminoalcohols. UPJOHN CO. 24 Aug., 1967 [26 Sept., 1966], No. 39082/67. Heading C2C. Novel compounds of Formula II wherein n is 1-4; -N Z is a heterocyclic radical with 5-10 atoms in the ring; R<SP>1</SP>, R<SP>11</SP> and R<SP>111</SP> are selected from hydrogen atoms, halogen atoms, C 1-6  alkyl, C 1-6  alkoxy and -CF 3  radicals; and R 1 , R 2  and R 3  are selected from hydrogen atoms, C 1-6  alkyl, C 1-6  alkoxy and -CF 3  radicals and their C 1-4  alkyl ethers, esters with C 2-8  straight-chain alkanoic acids, benzoic acid, mono-substituted benzoic acids, phenylacetic acid and phenyl-propionic acid, N-oxides, acid addition salts and quaternary C 1-12  alkyl ammonium halide salts are prepared by the following processes: (a) where the free hydroxy compound is required by treating a compound of Formula I with a Grignard reagent V wherein X is iodine or bromine, followed by decomposition of the resultant complex with water, (b) where the ether is required, by treating a compound II with sodamide in liquid ammonia followed by an alkyl bromide or iodide, (c) where the ester is required, by treating a compound I with butyl lithium and treating the salt formed with the appropriate acyl chloride, and (d) where the N-oxide is required, by treating a compound I with a peracid, followed in (a), (b), (c) or (d), where desired, by salt formation. Electrocardiographic jellies contain as the active ingredient a quaternary ammonium halide salt of compounds (II). A suitable jelly contains 5 parts glycerol, 10 parts starch, 60 parts quaternary ammonium salt and 100 parts water. The starting materials of Formula I are prepared by reacting the appropriate cycloalkanone with an heterocyclic amine to form an enamine and reacting this enamine with the appropriate benzoyl chloride, the benzoyl radical of which attaches itself to the 2-position of the cycloalkenyl moiety of the enamine. After hydrolysis the 2-(benzoyl or substituted benzoyl)-cycloalkanone is reacted with the appropriate heterocyclic amine. The thus-obtained (phenyl or substituted phenyl) (2-heterocyclicamino-1-cycloalken-1-yl) ketone is hydrogenated to give the starting material I. Pharmaceutical compositions comprise the compounds (II) and a carrier therefor. Compositions may be in a form suitable for enteral or parenteral administration and are useful in the treatment of oedema associated with hepatic disease, oedema and toxaemia of pregnancy, hypertensive vascular disease, premenstrual fluid retention and congestive heart failure.
The aim of the study is to discover if PTNS can be used to reduce the symptoms in those patients with tenesmus due to their pelvic floor disorders. These pelvic floor disorders include rectal cancer in situ, Anterior Resection Syndrome developed after rectal-cancer treatment, or gynaecological problems. Gynaecological problems that can cause tenesmus include radiotherapy for gynaecological cancer, ovarian cysts, pelvic organ prolapse and hysterectomy.

Currently, there is a lack of treatment options available to manage patients with tenesmus and it is hoped that PTNS will provide a simple, non-invasive treatment to this wide patient group with distressing symptoms. Assessment of symptom improvement will be used by analysing the change in scores on the COREFO, e-PAQ and HADS questionnaires, which will be completed pre and post treatment. COREFO is a validated questionnaire which includes questions specifically relating to tenesmus. e-PAQ is a validated questionnaire which looks at all aspects of the pelvic floor (bowel, urinary, vaginal, sexual) along with quality of life. HADS is a validated questionnaire classifying the patient's degree of anxiety and depression as either "normal", "borderline abnormal" or "abnormal".

There have been two pilot studies looking into the effect of PTNS in improving symptoms in Anterior Resection Syndrome patients. However, full papers have not been published of this data. These two studies assessed symptom improvement using questionnaires, but they did not use COREFO, e-PAQ or HADS, or include patients who currently have rectal cancer (i.e. not Anterior Resection Syndrome patients) or gynaecological problems and have the same tenesmus symptoms. Thus this makes this research an original proposal. e-PAQ is widely used in STH to assess pelvic floor symptoms, and thus its use here enables comparison with other patient groups who also have PTNS as a treatment option.
FIELD: medicine. ^ SUBSTANCE: invention refers to pharmacology and medicine, particularly to endocrinology. A method for making proinsulin preparation consists that in 1-50 % aqueous polyethylene glycol with molar mass 0.4-40 kDa pre-exposed to ionising radiation in amount 1.0-5.0 Mrad in acid medium at pH 2.5 - 4.5 with calcium and/or zinc cations added to final concentration of 5-10 mm, proinsulin is introduced to final concentration of 1-10 mg/ml in the ratio of polyethylene glycol to proinsulin equal (1-500)/1. The mixture is stirred to prepare a homogeneous transparent or slightly opalescent solution. ^ EFFECT: use of the method allows simplifying process for making proinsulin preparation and ensuring possibility of its application as a hypoglycaemic agent and maintenance of activity at pH 2-3 and room temperature. ^ 4 cl, 1 tbl, 4 ex
FIELD: medicine. SUBSTANCE: invention can be used in neurology, neurostomatology, maxillofacial surgery for treatment of patients with trifacial neuralgia. Method involves oral intake of glycerol in the morning in the dose 0.5 g per 1 kg of patient weight. Then kenalog (40 mg), vitamin B 12  (500 mg) and lidocaine (4 ml of 2% solution) is administrated in a single syringe to demyelinization focus in the second and the third branch of trigeminal nerve in region of round and oval holes. Then berlithion is administrated intravenously in the dose 300 mg, 2 times per 24 h with interval for 10-12 h. On the next day milgamma is administrated intramuscularly in the dose 2.0 ml and by alternating with blockades in every other day in further. Treatment course is 3-5 blockades. Method enhances effectiveness of treatment by reducing neurovascular conflict and activation of remyelinization process. EFFECT: improved treatment method. 1 ex
[Problem] To provide a nucleoside that is more practical for RNA pharmaceuticals and other applications and a use therefor. [Solution] A nucleoside derivative indicated by formula (1) or (2) or a salt thereof. (In formula (1), R1 indicates a hydrogen atom, a hydroxyl group, a hydroxyl group having a hydrogen atom substituted by an alkyl group or an alkenyl group, or a protected group. In formula (2), X indicates a halogen atom. In formulas (1) and (2), R2 and R4 can be the same or different and indicate a hydrogen atom, a protecting group for a hydroxyl group, a phosphate group, a protected phosphate group, or P(=0)nR5R6 (n indicates 0 or 1 and R5 and R6 can be the same or different and indicate either a hydrogen atom, a hydroxyl group, a protected hydroxyl group, a thiol group, a protected thiol group, a lower alkoxy group, a cyano lower alkoxy group, an amino group, or a substituted amino group. When n is 1, however, R5 and R6 are never both hydrogen atoms.) R3 indicates NHR7 having a linking group for each (R7 indicating a hydrogen atom, an alkyl group, an alkenyl group, or a protecting group for an amino group), an azide group, an amidino group, or a guanidino group. B indicates a purine-9-yl group, a 2-oxo-pyrimidin-1-yl group, a substituted purine-9-il group, or a substituted 2-oxo-pyrimidin-1-yl group.)
A method for establishing a decision tree for disease prediction is provided. The method receives a plurality of physiological measurement data corresponding to different diseases. The method classifies the physiological measurement data corresponding to the purpose. The method calculates at least one cutting point of the physiological measurement data. The method branches the decision tree corresponding to the at least one cutting point. The method prunes the decision tree to complete the establishment of the decision tree. The present invention can assist doctors in medical diagnosis, give preventive medication in advance based on the prediction results, and calculate the data of each terminal branch of the decision tree to obtain the probability of a single disease, which can improve the accuracy of more disease predictions.
PURPOSE:To obtain a new compound useful especially as a therapeutic agent for schizophrenia, having highly blocking action on dopamine receptor and slight alpha blocking action as adverse action. CONSTITUTION:A compound of formula I (R is 2-ethoxyphenyl) or its salt such as 7-{4-[40(2-ethoxyphenyl)-1-piperazinyl]butoxy}-3,4-dihydrocarbostyril. The compound of formula I is obtained by reacting a compound of formula II (X<1> is a halogen or a group such as mesyloxy or tosyloxy to cause the same substitution reaction as that of a halogen) with a compound of formula III in the absence of a solvent or in an inert solvent (e.g. acetonitrile) in the presence of a base (e.g. triethylamine) at room temperature to 200 deg.C. An alkali metal iodide compound (e.g. potassium iodide) is optionally added as a reaction promoter to carry out the reaction.
Pain in emergency departments (EDs) is often inadequately treated. The consequences of inadequate treatment of pain defined as "oligoanalgesia," can have a negative impact on patient outcomes. The main reasons for this include lack of appropriate pathways, incorrect habits and aversion to opioid use. Pain is a symptom present in 78% of patients entering emergency departments, and among the main causes is trauma. A multimodal approach to pain treatment is more effective and minimizes side effects such as nausea, vomiting, and drowsiness due to the use of some drugs such as opioids. Over the past fifteen years, numerous studies have demonstrated the effectiveness of pain treatment using Point-of-Care Ultrasound Guided Regional Anaesthesia (POCUS-GRA) even outside the operating room. This data registry aim is to describe the practice of Point-of-Care Ultrasound Guided Regional Anaesthesia (POCUS-GRA) in emergency departments of nosocomial hospitals where, the organizational structure, has already provided for the implementation of peripheral nerve blocks (PNB) in common clinical practice for the treatment of acute pain due to bone fractures.
Periarticular infiltration,performed intra-operatively,involves administering a 110 mL solution of ropivacaine 300mg, preservative free morphine 10mg, ketorolac 30mg mixed in normal saline into the knee. It will be administered as follows: the first 20mL aliquot is injected into the posterior capsule and the medial and lateral ligaments just prior to implantation; after the implants have been cemented and curing, another 20mL is infiltrated to the quadriceps and retinacular tissues. The remaining solution (\~60mL) is used to infiltrate the muscle, subcutaneous tissues.
The daily allowable dose is calculated according to the creatinine clearance rate. The carbapenems, cephalosporins and β-lactamase inhibitor compound preparations are administered in accordance with the dosage and usage required by the instructions, and the injection is generally 30 minutes.
OBJECTIVE: To investigate the potential of whole-body digital 11C-methionine (MET) PET/CT imaging for simultaneous evaluation of thoracic cancer patients suspected of local recurrence (LR) after stereotactic radiosurgery (SRS) for brain metastasis.
METHODS: A total of 45 lung or breast cancer patients suspected of LR after SRS were investigated using brain and whole-body MET-PET/CT scans. We compared the tumor-to-normal ratio (TNR) and maximum standardized uptake values (SUVmax) between patients with LR and radiation necrosis (RN) and performed receiver operating characteristic (ROC) analyses. We also investigated associations among extracranial recurrence, intracranial recurrence, primary site, and initial treatment type.
RESULTS: A total of 44 LR and 14 RN lesions were analyzed. In the ROC analyses for differentiating LR from RN, TNR showed higher area under the curve (AUC) (0.82) than SUVmax (0.79), and the cutoff TNR value (2.12) was higher than current cutoff values of conventional PET systems. The whole-body scans detected extracranial recurrences in 31.1% of the patients. Recurrence rates were not significantly correlated with existence of intracranial recurrence or primary site, but patients who underwent non-surgical treatment (consisting of stage III/ IV patients according to the Union for International Cancer Control TNM classification or small-cell lung cancer patients) showed significantly higher recurrence than the surgically treated patients (68.8% vs. 10.3%, p = 0.0001).
CONCLUSION: In digital MET-PET/CT imaging, TNR was a more useful parameter to differentiate LR from RN than SUVmax, and the cutoff value was higher than those with conventional PET systems. Additional whole-body scans could detect extracranial recurrence and would be especially useful for advanced thoracic cancer patients who underwent non-surgical treatment.
BACKGROUND: The ageing process is characterized by a change of body composition with an increase of fat mass and a reduction of muscle mass. Above a certain threshold these alterations configure a condition named sarcopenic obesity (SO). SO is associated with physical frailty in Asian and Brazilian populations. SO impacts on physical frailty in other ethnic groups but its influence on general frailty which is multidimensional and includes cognitive, social and physical factors, remain insufficiently explored in the Italian population.
METHODS: Frailty was measured in community dwelling Italian older adults enrolled in the FRASNET study with the frailty index (FI). The FI quantifies frailty as the ratio of the number of present health deficits to the total number of health deficits considered. Regression analyses were performed to assess the association between body composition categories and frailty. Classification and regression tree models were run to evaluate the frailty predictors.
RESULTS: One Thousand One Hundred Fourteen participants of the FRASNET study were included in the present analysis. The sample was composed for the 60.5% by females and its median age was 72 years. The median FI score was 0.11 (IQR 0.07-0.20); 234 individuals (21%) were frail (FI ≥ 0.25). SO (B 0.074, 95% C.I. 0.05-0.1, p < 0.001) and pre-sarcopenia (without obesity B 0.03, 95% C.I, 0.007-0.044, p < 0.001, with obesity B 0.11, 95% C.I. 0.05-0.16, p < 0.001) were associated with frailty. Fat mass percentage predicted frailty in people aged 65-70 years whereas, muscle strength predicted general frailty in people aged 70-81 years.
CONCLUSION: Pre-sarcopenia and SO represent potentially treatable predictors of frailty.
Enterally administrable diagnostic compositions for investigating alimentary functions comprise multiple units of a size of at the most 5 mm, preferably between 0.5 and 1.3 mm, in particular between 0.7 and 1.0 mm, each unit comprising a tracer-binding agent such as an ion exchange resin to which a radioactive tracer substance with a half-like of at the most 5 days, in particular ?99mTc, ?113mIn, ?111In and ?129Cs, is associated, the tracer-binding agent being formulated with pharmaceutically acceptable excipients, in particular granulating excipients in such a way that the exposure of the gastrointestinal mucosa to the tracer-binding agent is reduced and that the units do not disintegrate during the passage through the gastrointestinal tract. Preferred units comprise cross-sectionally substantially homogeneous multi-component cores in which the tracer-binding agent is granulated with one or more excipients and which are optionally coated with a diffusion coating permitting the labelling of the units to be performed at the site of use by immersing the units in a solution of tracer substance. Tracer-binding agents are normally present in an amount of about 2-20% by weight, preferably about 5-10% by weight, calculated on the units. Due to low leaching and the non-disintegrating properties, the composition can be used to investigate gastric emptying also of the last 20% of a food bolus, cf. Fig. 2 which illustrates the average gastric emptying pattern for 7 healthy volunteers (A) compared to the emptying from a person with the "Giesskannen" phenomenon (B).
Participants will be asked to use Alpha-Stim 60 minutes daily for 8 weeks. Active devices are programmed to emit a current intensity of 100 uA at 0.5 Hz and will be programmed to run for 60 minutes. Participants will not be able to adjust the settings on the devices.
The control group received conventional functional rehabilitation for 40 min/session, 2 sessions/day, 5 days/week for 4 weeks, 40 sessions in all. After 4-week intervention all subjects received conventional physical therapy only, 40 min/day, 5 days/week for 4 weeks. During the test period, general rehabilitation and drug treatment can be done at the same time.
Patients are admitted without a pre-determined discharge date. They do not receive a dedicated discharge appointment, and will not receive a follow up phone call 48 hours after discharge.
A soap that contains glacier silt that is harvested in its natural form from areas previously occupied by glaciers. Glacial silt is one of the finest materials known. This silt is as fine or finer than talcum powder. The silt is heated to 400 degrees, sifted for a uniform consistency, and blended into cleaning compositions (soaps) used for human skin. Applied to human skin, the composition acts as mild pumice. Glacier silt is distinctive from other abrasives or pumices because the silt, in its natural form, is made up of very fine particles and is essentially undetectable when being used.
DR vs DK is a multicentre, randomized, prospective, non-inferiority clinical trial designed to evaluate the efficacy and safety of DR crush over DK crush for patients with ULMb. More than 12 tertiary centres from Spain will participate including patients. Subjects with Medina 1,1,1 ULMb will be randomized in a 1:1 fashion to DR or DK crush. In order to avoid bias, the Sirolimus coronary stent will be used in all patients (UltimasterTM TanseiTM). The use of Intracoronary imaging techniques are recommended. The primary endpoint is target lesion failure (TLF) including target vessel myocardial infarction, cardiac death and TLR. Other endpoints address individual event of primary end-point, and target vessel revascularization. The safety objective is the ST. Recruitment began in January 2022 and will be completed in January 2024; 180 patients will be randomized.
In response to the psychosocial conditions arising from the ongoing pandemic, forest healing offers a corresponding solution. Forest healing activities have shown good adaptability in addressing conditions such as depression and anxiety. A systematic big data analysis paper highlights a significant decrease in depression following forest healing, with a Test overall effect Z=-6.204, as well as a similar significant reduction in anxiety with a Test overall effect Z=-4.183 (Yeon et al., 2021). For urban dwellers, a systematic review of big data on healing activities conducted in forest environments demonstrates significant normalization of systolic and diastolic blood pressure, an increase in the parasympathetic-to-sympathetic nervous system ratio, and a reduction in salivary cortisol concentration, with blood pressure shifting closer to normal indicators and salivary cortisol levels showing a downward trend after activities (Park et al., 2010; Qiu et al., 2022). Among populations exposed to chronic stressors, cortisol levels are higher compared to normal groups (Miller et al., 2007), and elevated salivary amylase activity is also noted compared to control groups (Vineetha et al., 2014). Therefore, forest healing significantly improves conditions like anxiety and depression, as reflected in the reduction of salivary cortisol concentrations.
Thyroid hormone drugs are natural or synthetic preparations containing tetraiodothyronine (T 4, levothyroxine) sodium or triiodothyronine (T 3, liothyronine) sodium or both. T 4 and T 3 are produced in the human thyroid gland by the iodination and coupling of the amino acid tyrosine. T 4 contains four iodine atoms and is formed by the coupling of two molecules of diiodotyrosine (DIT). T 3 contains three atoms of iodine and is formed by the coupling of one molecule of DIT with one molecule of monoiodotyrosine (MIT). Both hormones are stored in the thyroid colloid as thyroglobulin and released into the circulation. The major source of T 3 has been shown to be peripheral deiodination of T 4. T 3 is bound less firmly than T 4 in the serum, enters peripheral tissues more readily, and binds to specific nuclear receptor(s) to initiate hormonal, metabolic effects. T 4 is the prohormone which is deiodinated to T 3 for hormone activity. 

Thyroid hormone preparations belong to two categories: (1) natural hormonal preparations derived from animal thyroid, and (2) synthetic preparations. Natural preparations include desiccated thyroid and thyroglobulin. Desiccated thyroid is derived from domesticated animals that are used for food by man (either beef or hog thyroid), and thyroglobulin is derived from thyroid glands of the hog.

Liothyronine sodium injection (T 3) contains liothyronine (L-triiodothyronine or L-T 3), a synthetic form of a natural thyroid hormone, as the sodium salt. 

The structural and empirical formulas and molecular weight of liothyronine sodium are given below.

In euthyroid patients, 25 mcg of liothyronine is equivalent to approximately 1 grain of desiccated thyroid or thyroglobulin and 0.1 mg of L-thyroxine.

Each mL of liothyronine sodium injection (T 3) in amber glass vials contains, in sterile non-pyrogenic aqueous solution, liothyronine sodium equivalent to 10 mcg of liothyronine; alcohol, 6.8% by volume; anhydrous citric acid, 0.175 mg; ammonia, 2.19 mg, as ammonium hydroxide; Water for Injection, USP.
African Americans have a high risk of developing heart disease and stroke, and are more likely to die from heart-related illnesses than other racial and ethnic groups. A large majority of African Americans are descendants of both African and European ancestors who mixed five to six generations ago. Because only a few generations have passed since that time, it is still possible to identify specific genes, the basic units of heredity, as being either African or European in origin. This is a sub study of the Jackson Heart Study, which is examining the environmental and genetic factors that influence the development of heart disease in African Americans. In this study, researchers will examine genes from participants in the Jackson Heart Study to identify specific African and European genes that influence the development of heart disease in African American men and women.

This study will use genetic samples from individuals participating in the Jackson Heart Study. There will be no study visits for participants. Study researchers will examine the genetic samples and identify specific African and European genes that may influence the development of heart disease, high blood pressure, lipid disorders, left ventricular hypertrophy, and low birth weight.